Effect of host genetics on incidence of HIV neuroretinal disorder in patients with AIDS

Journal of Acquired Immune Deficiency Syndromes

Volumn 54, Issue 4, 2010, Pages 343-351

  Sezgin, Efe ^a   Hendrickson, Sher L ^a   Jabs, Douglas A ^b,c   Van Natta, Mark L ^c   Lewis, Richard A ^d   Troyer, Jennifer L ^e   O'Brien, Stephen J ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

^e SAIC FREDERICK INC   (United States)

Author keywords

AIDS; HIV 1; HIV neuroretinal disorder; host genetics

Indexed keywords

CHEMOKINE RECEPTOR CCR2; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CX3CR1; GAMMA INTERFERON; INTERLEUKIN 10; MONOCYTE CHEMOTACTIC PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; RANTES; STROMAL CELL DERIVED FACTOR 1; STROMAL CELL DERIVED FACTOR 3; UNCLASSIFIED DRUG; CCL5 PROTEIN, HUMAN; CCR2 PROTEIN, HUMAN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AFRICAN AMERICAN; AGE DISTRIBUTION; AIDS PATIENT; ARTICLE; CONTROLLED STUDY; EUROPEAN AMERICAN; FEMALE; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNOGENETICS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RACE DIFFERENCE; RETINA DISEASE; SEX RATIO; CAUCASIAN; CD4 LYMPHOCYTE COUNT; DISEASE COURSE; GENETIC PREDISPOSITION; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LONGITUDINAL STUDY; MIDDLE AGED; RESTRICTION MAPPING; VIROLOGY; VIRUS LOAD;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; CD4 LYMPHOCYTE COUNT; CHEMOKINE CCL5; DISEASE PROGRESSION; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENETIC VARIATION; GENOTYPE; HAPLOTYPES; HIV INFECTIONS; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; RECEPTORS, CCR2; RECEPTORS, CCR5; RESTRICTION MAPPING; RETINAL DISEASES; VIRAL LOAD;

EID: 77955483527     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e3181deaf4d     Document Type: Article

References (57)

1. Jabs DA. Ocular manifestations of HIV infection. Trans Am Ophthalmol Soc. 1995;93:623-683.
2. Jabs DA, Van Natta ML, Holbrook JT, et al. Longitudinal study of the ocular complications of AIDS: 1. Ocular diagnoses at enrollment. Ophthalmology. 2007;114:780-786.
3. Jabs DA, Van Natta ML, Holbrook JT, et al. Longitudinal study of the ocular complications of AIDS: 2. Ocular examination results at enrollment. Ophthalmology. 2007;114:787-793.
4. Freeman WR, Van Natta ML, Jabs D, et al. Vision function in HIV-infected individuals without retinitis: report of the Studies of Ocular Complications of AIDS Research Group. Am J Ophthalmol. 2008;145: 453-462.
5. Mueller AJ, Plummer DJ, Dua R, et al. Analysis of visual dysfunctions in HIV-positive patients without retinitis. Am J Ophthalmol. 1997;124: 158-167.
6. Plummer DJ, Marcotte TD, Sample PA, et al. Neuropsychological impairment-associated visual field deficits in HIV infection. HNRC Group. HIV Neurobehavioral Research Center. Invest Ophthalmol Vis Sci. 1999;40:435-442.
7. Shah KH, Holland GN, Yu F, et al. Contrast sensitivity and color vision in HIV-infected individuals without infectious retinopathy. Am J Ophthal-mol. 2006;142:284-292
8. An P, Nelson GW, Wang L, et al. Modulating influence on HIV/AIDS by interacting RANTES gene variants. Proc Natl Acad Sci\USA. 2002;99: 10002-10007.
9. Carrington M, O'Brien SJ. The influence of HLA genotype on AIDS. Annu Rev Med. 2003;54:535-551.
10. Hendrickson SL, Jacobson LP, Nelson GW, et al. Host genetic influences on highly active antiretroviral therapy efficacy and AIDS-free survival. J Acquir Immune Defic Syndr. 2008;48:263-271.
11. O'Brien SJ, Nelson GW. Human genes that limit AIDS. Nat Genet. 2004; 36:565-574.
12. O'Brien TR, McDermott DH, Ioannidis JP, et al. Effect of chemokine receptor gene polymorphisms on the response to potent antiretroviral therapy. AIDS. 2000;14:821-826.
13. Lin XH, Kashima Y, Khan M, et al. An immunohistochemical study of TNF-alpha in optic nerves from AIDS patients. Curr Eye Res. 1997;16: 1064-1068.
14. Madigan MC, Sadun AA, Rao NS, et al. Tumor necrosis factor-alpha (TNF-alpha)-induced optic neuropathy in rabbits. Neurol Res. 1996;18: 176-184.
15. Petrovich MS, Hsu HY, Gu X, et al. Pentoxifylline suppression of TNF-alpha mediated axonal degeneration in the rabbit optic nerve. Neurol Res. 1997;19:551-554.
16. Saadati HG, Khan IA, Lin XH, et al. Immunolocalization of IL-1beta and IL-6 in optic nerves of patients with AIDS. Curr Eye Res. 1999;19: 264-268.
17. Ho AS, Moore KW. Interleukin-10 and its receptor. Ther Immunol. 1994; 1:173-185.
18. Moore KW, de Waal Malefyt R, Coffman RL, et al. Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol. 2001;19:683-765.
19. Gasche C, Grundtner P, Zwirn P, et al. Novel variants of the IL-10 receptor 1 affect inhibition of monocyte TNF-alpha production. J Immunol. 2003; 170:5578-5582.
20. Grundtner P, Gruber S, Murray SS, et al. The IL-10R1 S138G loss-of-function allele and ulcerative colitis. Genes Immun. 2009;10:84-92.
21. Crawley E, Kay R, Sillibourne J, et al. Polymorphic haplotypes of the interleukin-10 5' flanking region determine variable interleukin-10 transcription and are associated with particular phenotypes of juvenile rheumatoid arthritis. Arthritis Rheum. 1999;42:1101-1108.
22. Mormann M, Rieth H, Hua TD, et al. Mosaics of gene variations in the Interleukin-10 gene promoter affect interleukin-10 production depending on the stimulation used. Genes Immun. 2004;5:246-255.
23. Shin HD, Winkler C, Stephens JC, et al. Genetic restriction of HIV-1 pathogenesis to AIDS by promoter alleles of IL10. Proc Natl Acad Sci\USA. 2000;97:14467-14472.
24. Turner DM, Williams DM, Sankaran D, et al. An investigation of polymorphism in the interleukin-10 gene promoter. Eur J Immunogenet. 1997;24:1-8.
25. Barrett JC, Fry B, Maller J, et al. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics. 2005;21:263-265.
26. Martin MP, Dean M, Smith MW, et al. Genetic acceleration of AIDS progression by a promoter variant of CCR5. Science. 1998;282: 1907-1911.
27. Liu H, Chao D, Nakayama EE, et al. Polymorphism in RANTES chemokine promoter affects HIV-1 disease progression. Proc Natl Acad Sci\USA. 1999;96:4581-4585.
28. Tarwater PM, Mellors J, Gore ME, et al. Methods to assess population effectiveness of therapies in human immunodeficiency virus incident and prevalent cohorts. Am J Epidemiol. 2001;154:675-681.
29. Gibson AW, Edberg JC, Wu J, et al. Novel single nucleotide polymorphisms in the distal IL-10 promoter affect IL-10 production and enhance the risk of systemic lupus erythematosus. J Immunol. 2001; 166:3915-3922.
30. Dumont FJ. Therapeutic potential of IL-10 and its viral homologues: an update. Expert Opinion on Therapeutic Patents. 2003;13:1551-1577.
31. Vasilescu A, Heath SC, Ivanova R, et al. Genomic analysis of Th1-Th2 cytokine genes in an AIDS cohort: identification of IL4 and IL10 haplotypes associated with the disease progression. Genes Immun. 2003; 4:441-449.
32. Oleksyk TK, Shrestha S, Truelove AL, et al. Extended IL10 haplotypes and their association with HIV progression to AIDS. Genes Immun. 2009; 10:309-322.
33. Berger EA, Murphy PM, Farber JM. Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. Annu Rev Immunol. 1999;17:657-700.
34. Cocchi F, DeVico AL, Garzino-Demo A, et al. Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells. Science. 1995;270:1811-1815.
35. Gonzalez E, Dhanda R, Bamshad M, et al. Global survey of genetic variation in CCR5, RANTES, and MIP-1alpha: impact on the epidemiology of the HIV-1 pandemic. Proc Natl Acad Sci\USA. 2001;98:5199-5204.
36. McDermott DH, Beecroft MJ, Kleeberger CA, et al. Chemokine RANTES promoter polymorphism affects risk of both HIV infection and disease progression in the Multicenter AIDS Cohort Study. AIDS. 2000;14: 2671-2678.
37. Trkola A, Gordon C, Matthews J, et al. The CC-chemokine RANTES increases the attachment of human immunodeficiency virus type 1 to target cells via glycosaminoglycans and also activates a signal trans-duction pathway that enhances viral infectivity. J Virol. 1999;73: 6370-6379.
38. Garcia-Moruja C, Rueda P, Torres C, et al. Molecular phenotype of CXCL12beta 3'UTR G801A polymorphism (rs1801157) associated to HIV-1 disease progression. Curr HIV Res. 2009;7:384-389.
39. Tiensiwakul P. Stromal cell-derived factor (SDF) 1-3'A polymorphism may play a role in resistance to HIV-1 infection in seronegative high-risk Thais. Intervirology. 2004;47:87-92.
40. Brambilla A, Villa C, Rizzardi G, et al. Shorter survival of SDF1-3'A/3'A homozygotes linked to CD4+ T cell decrease in advanced human immunodeficiency virus type 1 infection. J Infect Dis. 2000;182:311-315.
41. Puissant B, Roubinet F, Massip P, et al. Analysis of CCR5, CCR2, CX3CR1, and SDF1 polymorphisms in HIV-positive treated patients: impact on response to HAART and on peripheral T lymphocyte counts. AIDS Res Hum Retroviruses. 2006;22:153-162.
42. Winkler C, Modi W, Smith MW, et al. Genetic restriction of AIDS pathogenesis by an SDF-1 chemokine gene variant. ALIVE Study, Hemophilia Growth and Development Study (HGDS), Multicenter AIDS Cohort Study (MACS), Multicenter Hemophilia Cohort Study (MHCS), San Francisco City Cohort (SFCC). Science. 1998;279:389-393.
43. Bogner JR, Lutz B, Klein HG, et al. Association of highly active antiretroviral therapy failure with chemokine receptor 5 wild type. HIV Med. 2004;5:264-272.
44. Wit FW, van Rij RP, Weverling GJ, et al. CC chemokine receptor 5 delta32 and CC chemokine receptor 2 64I polymorphisms do not influence the virologic and immunologic response to antiretroviral combination therapy in human immunodeficiency virus type 1-infected patients. J Infect Dis. 2002;186:1726-1732.
45. Yamashita TE, Phair JP, Munoz A, et al. Immunologic and virologic response to highly active antiretroviral therapy in the Multicenter AIDS Cohort Study. AIDS. 2001;15:735-746.
46. Lathey JL, Tierney C, Chang SY, et al. Associations of CCR5, CCR2, and stromal cell-derived factor 1 genotypes with human immunodeficiency virus disease progression in patients receiving nucleoside therapy. J Infect Dis. 2001;184:1402-1411.
47. Scaravilli F, Bazille C, Gray F. Neuropathologic contributions to understanding AIDS and the central nervous system. Brain Pathol. 2007;17:197-208.
48. Levy RM, Bredesen DE, Rosenblum ML. Neurological manifestations of the acquired immunodeficiency syndrome (AIDS): experience at UCSF and review of the literature. J Neurosurg. 1985;62:475-495.
49. Tenhula WN, Xu SZ, Madigan MC, et al. Morphometric comparisons of optic nerve axon loss in acquired immunodeficiency syndrome. Am J Ophthalmol. 1992;113:14-20.
50. Kaul M, Lipton SA. Mechanisms of neuroimmunity and neurodegenera-tion associated with HIV-1 infection and AIDS. J Neuroimmune Pharmacol. 2006;1:138-151.
51. Kaul M, Garden GA, Lipton SA. Pathways to neuronal injury and apoptosis in HIV-associated dementia. Nature. 2001;410:988-994.
52. Bruce-Keller AJ, Chauhan A, Dimayuga FO, et al. Synaptic transport of human immunodeficiency virus-Tat protein causes neurotoxicity and gliosis in rat brain. J Neurosci. 2003;23:8417-8422.
53. Li W, Galey D, Mattson MP, et al. Molecular and cellular mechanisms of neuronal cell death in HIV dementia. Neurotox Res. 2005;8:119-134.
54. Asensio VC, Campbell IL. Chemokines in the CNS: plurifunctional mediators in diverse states. Trends Neurosci. 1999;22:504-512.
55. Miller RJ, Meucci O. AIDS and the brain: is there a chemokine connection? Trends Neurosci. 1999;22:471-479.
56. Hesselgesser J, Taub D, Baskar P, et al. Neuronal apoptosis induced by HIV-1 gp120 and the chemokine SDF-1 alpha is mediated by the chemokine receptor CXCR4. Curr Biol. 1998;8:595-598.
57. Kaul M, Lipton SA. Chemokines and activated macrophages in HIV gp120-induced neuronal apoptosis. Proc Natl Acad Sci\USA. 1999;96: 8212-8216.